Should I buy or sell Generation Bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares. View GBIO analyst ratings or view top-rated stocks .

What is Generation Bio's stock price target for 2024?

6 brokerages have issued 1-year price objectives for Generation Bio's shares. Their GBIO share price targets range from $2.23 to $14.00. On average, they predict the company's share price to reach $8.56 in the next twelve months. This suggests a possible upside of 400.4% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts .

How have GBIO shares performed in 2023?

Generation Bio's stock was trading at $3.93 at the beginning of the year. Since then, GBIO shares have decreased by 56.5% and is now trading at $1.71. View the best growth stocks for 2023 here .

Are investors shorting Generation Bio?

Generation Bio saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,090,000 shares, an increase of 76.6% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 569,000 shares, the days-to-cover ratio is currently 5.4 days. Currently, 6.3% of the company's shares are sold short. View Generation Bio's Short Interest .

When is Generation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our GBIO earnings forecast .

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company earned $2.15 million during the quarter, compared to analysts' expectations of $2.26 million.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU) , NVIDIA (NVDA) , Overstock.com (OSTK) , Boeing (BA) , Pure Storage (PSTG) , Mastercard (MA) , QUALCOMM (QCOM) , Riot Platforms (RIOT) , Twilio (TWLO) and Enphase Energy (ENPH) .

When did Generation Bio IPO?

(GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Generation Bio's major shareholders?

Generation Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (12.79%), TD Asset Management Inc (0.62%), Wellington Management Group LLP (0.27%), GSA Capital Partners LLP (0.06%), American Century Companies Inc. (0.05%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr , Evan Spiegel , Geoff Mcdonough , Jason P Rhodes , Matthew Stanton , Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends .

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Generation Bio (GBIO) Stock Price, News & Analysis

$1.71

-0.06 (-3.39%)

(As of 12/8/2023 08:57 PM ET)

Compare

Today's Range: $1.60
▼
$1.93
50-Day Range: $0.91
▼
$3.35
52-Week Range: $0.86
▼
$7.35

Volume: 688,900 shs
Average Volume: 392,424 shs
Market Capitalization: $112.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.56

Generation Bio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 400.4% Upside
$8.56 Price Target
Short Interest: Bearish
6.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 8 Articles This Week
Insider Trading: Acquiring Shares
$18,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.88) to ($1.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

335th out of 942 stocks

Biotechnology Industry

9th out of 41 stocks

3.2

Analyst's Opinion

Consensus Rating
Generation Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.56, Generation Bio has a forecasted upside of 400.4% from its current price of $1.71.
Amount of Analyst Coverage
Generation Bio has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.34% of the float of Generation Bio has been sold short.
Short Interest Ratio / Days to Cover
Generation Bio has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Generation Bio has recently increased by 76.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Generation Bio does not currently pay a dividend.
Dividend Growth
Generation Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GBIO.

1.9

News and Social Media Coverage

News Sentiment
Generation Bio has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Generation Bio this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Generation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Generation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
20.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.81% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Generation Bio are expected to grow in the coming year, from ($1.88) to ($1.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Generation Bio is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Generation Bio is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Generation Bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Generation Bio Stock (NASDAQ:GBIO)

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GBIO Stock News Headlines

December 7, 2023 | finance.yahoo.com

Charles Rowland Bought 179% More Shares In Generation Bio

December 6, 2023 | finance.yahoo.com

Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)

December 11, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 5, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Generation Bio Co. Lowered by William Blair (NASDAQ:GBIO)

December 4, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Generation Bio Co. Increased by Analyst (NASDAQ:GBIO)

November 30, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)

November 29, 2023 | msn.com

Generation Bio cuts its payroll by 40 percent in latest restructuring move

November 29, 2023 | bizjournals.com

Moderna-partnered gene therapy firm to lay off 68, including two execs

December 11, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 29, 2023 | marketwatch.com

Generation Bio Begins Strategic Reorganization, With 40% Headcount Cut

November 29, 2023 | finance.yahoo.com

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

November 11, 2023 | markets.businessinsider.com

Hold Rating on Generation Bio: Innovations in Immune-Quiet DNA and ctLNP Delivery System Yet Uncertain Timeline for Hemophilia A Program

November 11, 2023 | markets.businessinsider.com

Analyst Upholds Buy Rating for Generation Bio Based on 3Q23 Earnings and Strong Financial Health

November 10, 2023 | msn.com

Generation Bio GAAP EPS of -$0.43

November 9, 2023 | finance.yahoo.com

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

October 26, 2023 | finance.yahoo.com

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

October 23, 2023 | msn.com

JMP Securities Downgrades Generation Bio (GBIO)

October 20, 2023 | markets.businessinsider.com

JMP Securities downgrades Generation Bio (GBIO) to a Hold

October 19, 2023 | msn.com

TD Cowen Downgrades Generation Bio (GBIO)

October 18, 2023 | finance.yahoo.com

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

September 27, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), Teladoc (TDOC) and Edwards Lifesciences (EW)

September 19, 2023 | finance.yahoo.com

Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

September 18, 2023 | finance.yahoo.com

We're Not Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn

August 16, 2023 | msn.com

JP Morgan Maintains Generation Bio (GBIO) Neutral Recommendation

August 7, 2023 | msn.com

Generation Bio: Novel But Preclinical, Interesting But Without Data

August 7, 2023 | finanznachrichten.de

Generation Bio Co.: Generation Bio Reports Second Quarter 2023 Financial Results

August 3, 2023 | msn.com

Wedbush Reiterates Generation Bio (GBIO) Outperform Recommendation

See More Headlines

Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/10/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GBIO
CUSIP: N/A
CIK: 1733294
Web: generationbio.com
Phone: 617-655-7500
Fax: N/A
Employees: 150
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.56
High Stock Price Target: $14.00
Low Stock Price Target: $2.23
Potential Upside/Downside: +400.4%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-136,640,000.00
Net Margins: N/A
Pretax Margin: -4,092.23%
Return on Equity: -47.27%
Return on Assets: -31.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.07
Quick Ratio: 9.07

Sales & Book Value

Annual Sales: $3.03 million
Price / Sales: 37.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.75 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 66,078,000
Free Float: 52,334,000
Market Cap: $112.99 million
Optionable: Not Optionable
Beta: 2.49

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Cameron Geoffrey McDonough M.D. (Age 53)
President, CEO & Director
Comp: $939.09k
Dr. Matthew Norkunas M.B.A. (Age 45)
M.D., Chief Financial Officer
Comp: $611.11k
Dr. Matthew Stanton Ph.D. (Age 50)
Chief Scientific Officer
Comp: $654.83k
Dr. Douglas Kerr M.B.A. (Age 56)
M.D., Ph.D., Chief Medical Officer
Comp: $659.1k
Dr. Tracy Zimmermann Ph.D. (Age 53)
Chief Development Officer
Comp: $622.74k
Dr. Mark D. Angelino Ph.D. (Age 50)
Co-Founder
Dr. Robert Kotin Ph.D. (Age 67)
Co-Founder
Ms. Antoinette Paone M.B.A. (Age 45)
M.S., Chief Operating Officer
Ms. Yalonda Howze J.D. (Age 51)
Chief Legal Officer & Secretary
Ms. Jasmin Tower
Senior Vice President of People & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares.
View GBIO analyst ratings or view top-rated stocks.
What is Generation Bio's stock price target for 2024?: 6 brokerages have issued 1-year price objectives for Generation Bio's shares. Their GBIO share price targets range from $2.23 to $14.00. On average, they predict the company's share price to reach $8.56 in the next twelve months. This suggests a possible upside of 400.4% from the stock's current price.
View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts.
How have GBIO shares performed in 2023?: Generation Bio's stock was trading at $3.93 at the beginning of the year. Since then, GBIO shares have decreased by 56.5% and is now trading at $1.71.
View the best growth stocks for 2023 here.
Are investors shorting Generation Bio?: Generation Bio saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,090,000 shares, an increase of 76.6% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 569,000 shares, the days-to-cover ratio is currently 5.4 days. Currently, 6.3% of the company's shares are sold short.
View Generation Bio's Short Interest.
When is Generation Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our GBIO earnings forecast.
How were Generation Bio's earnings last quarter?: Generation Bio Co. (NASDAQ:GBIO) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company earned $2.15 million during the quarter, compared to analysts' expectations of $2.26 million.

What other stocks do shareholders of Generation Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).
When did Generation Bio IPO?: (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Generation Bio's major shareholders?: Generation Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (12.79%), TD Asset Management Inc (0.62%), Wellington Management Group LLP (0.27%), GSA Capital Partners LLP (0.06%), American Century Companies Inc. (0.05%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas.
View institutional ownership trends.
How do I buy shares of Generation Bio?: Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GBIO) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial